<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01920412</url>
  </required_header>
  <id_info>
    <org_study_id>LA-AP-01</org_study_id>
    <nct_id>NCT01920412</nct_id>
  </id_info>
  <brief_title>Feasibility and Safety Study of LAmbre Left Atrial Appendage Occluder</brief_title>
  <official_title>A Prospective, Non-randomized, Multicenter, Open-label, Non-comparative, First-in-Man Study to Evaluate the Feasibility and Safety of LAmbre Left Atrial Appendage Occluder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lifetech Scientific (Shenzhen) Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Lifetech Scientific (Shenzhen) Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study mainly evaluated the feasibility and safety of LAmbre Left Atrial Appendage&#xD;
      Occluder which is to prevent ischemic stroke caused by atrial fibrillation(AF).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Atrial fibrillation (AF) is a common arrhythmia, its incidence increases with age. Thrombosis&#xD;
      shed off caused by AF is one of the major causes of stroke. Most patients with AF suffer&#xD;
      ischemic stroke that the thrombosis was from the left atrial appendage(LAA). The majority of&#xD;
      patients with atrial fibrillation, the blood clots come from the left atrial appendage, so&#xD;
      close the left atrial appendage can reduce cycle thromboembolism of the patients with AF. Now&#xD;
      patients have cardiac surgery and risk at left atrium related thromboembolism, the surgery&#xD;
      has been conventional perform the left atrial appendage closed surgery.&#xD;
&#xD;
      However, surgical left atrial appendage ligation is difficult to be completely closed to the&#xD;
      left atrial appendage,internal medicine intervention methods of surgical closure the left&#xD;
      atrial appendage is relatively simple, minimally invasive, high success rate and is expected&#xD;
      to be widely used.&#xD;
&#xD;
      Several versions of LAA occlusion devices have been developed.LAA occluder of Lifetech&#xD;
      consists of a umbrella, cover and conveyor; The umbrella composed of multiple umbrella and&#xD;
      covered the ePTFE membrane.This study mainly evaluated the feasibility and safety of LAmbre&#xD;
      Left Atrial Appendage Occluder! Through the femoral vein puncture; insert inter atrial septum&#xD;
      puncture device; puncture a small hole in the atrial septal, delivery sheath is inserted in&#xD;
      the femoral vein puncture site and across the atrial septal reach the left atrial appendage,&#xD;
      establishment of the channel. Through the built-channel sent the LAA occluder to the left&#xD;
      atrial appendage by the delivery cable; The LAA occlude will be fixed in the left atrial&#xD;
      appendage, close the entrance of the left atrial appendage meanwhile and block blood flow;&#xD;
      then eliminate the risk of blood clots due to atrial fibrillation, prevention stroke.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2012</start_date>
  <completion_date type="Actual">September 2014</completion_date>
  <primary_completion_date type="Actual">October 2013</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The feasibility end-point</measure>
    <time_frame>30 days</time_frame>
    <description>stable device placement in left atrial appendage as assessed by angiography and trans-esophageal(TEE)and successful sealing around the device LAA orifice with the device(jet&lt;3mm in width) as measured by TEE at 30 days after device implant</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The composite safety and efficacy end-point</measure>
    <time_frame>12 months</time_frame>
    <description>Safety:freedom of major adverse events such as pericardial effusion. Successful closure without evidence of residual shunt and ischemic stroke after 1 year confirmed by trans-esophageal(TEE) and electrocardiograph.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Atrial Fibrillation</condition>
  <condition>Stroke</condition>
  <arm_group>
    <arm_group_label>Left Atrial Appendage Occluder</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Adopted non-comparative arm on Left Atrial Appendage Occluder.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>LAmbre Left Atrial Appendage(LAA) Occluder</intervention_name>
    <description>Implanting the LAmbre Left Atrial Appendage Occluder to close the left atrial appendage</description>
    <arm_group_label>Left Atrial Appendage Occluder</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patient is ≥18 years of age;&#xD;
&#xD;
          2. Chronic atrial fibrillation ≥3 months; paroxysmal, persistent or permanent&#xD;
             non-valvular AF;&#xD;
&#xD;
          3. CHADS2-VAS score 2 or higher;&#xD;
&#xD;
          4. Patient can understand the trial purpose, voluntarily join this clinical trial with&#xD;
             informed consent;&#xD;
&#xD;
          5. Patient voluntarily completes the follow-up and follow-up inspection in accordance&#xD;
             with the clinical trials process.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  A. Clinical exclusion criteria&#xD;
&#xD;
               1. Presence of rheumatic, degenerative or congenital valvular heart diseases,&#xD;
&#xD;
               2. The diameter of left atrial ≥65 mm;&#xD;
&#xD;
               3. LAA size &lt; 12mm or &gt; 30 mm&#xD;
&#xD;
               4. Left atrium has been removed;&#xD;
&#xD;
               5. Heart transplantation patients;&#xD;
&#xD;
               6. Symptomatic patients with carotid artery disease (such as carotid stenosis ≥&#xD;
                  50%);&#xD;
&#xD;
               7. Acute myocardial infarction or unstable angina;&#xD;
&#xD;
               8. Decompensated heart failure (New York Heart Association functional class III-IV);&#xD;
&#xD;
               9. Recent myocardial infarction (&lt; 3 months);&#xD;
&#xD;
              10. Patients with an atrial septal defect or received an atrial septal occluder. The&#xD;
                  patient has an ablation procedure planned within 30 days of potential LAmbre&#xD;
                  Occluder implant&#xD;
&#xD;
              11. The patient has a planned cardioversion 30 days post implant of the LAmbre&#xD;
                  Occluder&#xD;
&#xD;
              12. Patient who after artificial mechanical heart valve replacement operation;&#xD;
&#xD;
              13. Uncontrolled Heart rate ≥ 110 beats / min17) History stroke or TIA within 30&#xD;
                  days;&#xD;
&#xD;
              14. Presence of complex aortic plaque(4mm) in ascending aorta;&#xD;
&#xD;
              15. Cardiac tumors or other malignancy with estimated life expectancy u less than 2&#xD;
                  years;&#xD;
&#xD;
              16. Have thrombocytopenia (platelet 《105 / μl) or anemia（Hb&lt;10g/dl）;&#xD;
&#xD;
              17. Women who is pregnancy or plan to pregnancy during the trial period;&#xD;
&#xD;
              18. Presence of active sepsis or endocarditis;&#xD;
&#xD;
              19. Patient participated in the other trials;&#xD;
&#xD;
              20. The investigators expect the patient not be able to complete the trial according&#xD;
                  to requirements.&#xD;
&#xD;
        B. Esophageal ultrasonic exclusion criteria&#xD;
&#xD;
          1. LVEF≤30%;&#xD;
&#xD;
          2. Presence of left atrial appendage thrombus;&#xD;
&#xD;
          3. High risk PFO patients(presence of atrial septal aneurysm);&#xD;
&#xD;
          4. Have obvious mitral valve stenosis (the area of mitral valve≤ 2 cm2);&#xD;
&#xD;
          5. Have obvious and unexplained pericardial effusion(≥4 cm2).&#xD;
&#xD;
          6. Presence of complex aortic plague(≥4 mm) in ascending aorta.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yat-Yin YY Lam, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Prince of Wales Hospital, Shatin, Hong Kong</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Muhammad Munawar, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Binawaluya Hospital, Indonesia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lan Hieu Nguyen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hanoi Heart Hospital, Vietnam</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yan Yao, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fuwai Hospital, China</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Congxin Huang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Renmin Hospital of Wuhan University,China</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Prince of Wales Hospital</name>
      <address>
        <city>Hong Kong</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2013</verification_date>
  <study_first_submitted>August 8, 2013</study_first_submitted>
  <study_first_submitted_qc>August 8, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 12, 2013</study_first_posted>
  <last_update_submitted>August 6, 2018</last_update_submitted>
  <last_update_submitted_qc>August 6, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 7, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Atrial fibrillation</keyword>
  <keyword>Thrombosis</keyword>
  <keyword>Ischemic stroke</keyword>
  <keyword>Left atrial appendage occluder</keyword>
  <keyword>Intervention method</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

